Navigation Links
Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Date:11/20/2007

CRANBURY, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the Lazard Capital Markets Fourth Annual Healthcare Conference in New York City on Tuesday, November 27th at 11:30 am ET at The New York Palace Hotel.

A live audio web cast of the presentation will be available to all interested parties through the Investors section of Amicus' website at http://www.amicustherapeutics.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has two product candidates in Phase II clinical trials, Amigal(TM) for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company announced positive data from Phase I clinical trials of AT2220 for the treatment of Pompe disease in October 2007.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forw
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Neogen Corporation (Nasdaq: NEOG ) announced today ... 2015 fiscal year, which ended Aug. 31, was $8,883,000 ... $7,839,000 in the first quarter of last year. Adjusted ... earnings per share in the current quarter were $0.24, ... quarter revenues increased 15% to $67,599,000, from the previous ...
(Date:9/22/2014)... METTLER TOLEDO is pleased to ... device CNS110 ScanTape™ . Replacing a traditional ... greater ease and accuracy for transport and logistics ... enhance productivity—an important benefit for load planning and ... profits. , Usable at any point in ...
(Date:9/21/2014)... scientists have discovered how to produce ultra-thin "diamond nanothreads" ... than that of today,s strongest nanotubes and polymers. A ... by John V. Badding, a professor of chemistry at ... September 2014 issue of the journal Nature Materials ... discovery is intriguing because the threads we formed have ...
(Date:9/20/2014)... MediVet America and NanoFiber ... surgery at the specialized Wolvega Horse Clinic. , Due ... tendon was ruptured 90% and her deep digital flexor ... death sentence for a horse. , The clinic has ... . This revolutionary regenerative option for ruptured tendons ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7ScanTape™ Handheld Dimensioner Increases Processing Volume 2Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... to fuel requires several steps: chemical pretreatment to break ... to remove the toxic chemicals required in pretreatment, and ... Virginia Tech researchers have discovered an enzyme mixture that ... biomass (hydrolysate), meaning that the detoxification step is unnecessary, ...
... 2011 Cadence Pharmaceuticals, Inc. (Nasdaq: ... commercializing proprietary product candidates principally for use in the hospital ... and full year ended December 31, 2010 financial results on ... host a conference call and live webcast to discuss the ...
... Bulletin Board: GOVX ), an Atlanta-based biotechnology company ... its financial results for the fourth quarter and year ended ... of $478,784 for the fourth quarter ended December 31, 2010, ... comparable period in 2009. For the full year of 2010, ...
Cached Biology Technology:Enzyme cocktail could eliminate a step in biofuel process 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... biology professor will study multifunctional and specialized spinal ... a National Science Foundation grant in the amount ... Berkowitz, professor in the Department of Biology, OU ... the differences between the multifunctional and specialized spinal ... use and what connections they make. Berkowitz ...
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... aging and many age-related diseases is oxidative stress," says the ... of pathology. The skin of a bitten apple will brown ... that is a good metaphor for the damage that oxidative ... over time. , Humans and other organisms depend on oxygen ...
... Avoiding quicksand along the banks of the Ivindo River in ... patterns of electricity created by fish in the water. ... groups of local electric fish have different DNA, different communication ... have found a case where two types of electric signals ...
... Using a "clot buster" drug normally reserved for treating patients ... double the number of patients who could be revived from ... more than 260,000 people a year nationwide ?and at least ... as a new therapy for this abrupt and catastrophic loss ...
Cached Biology News:Free radical cell death switch identified 2Electric fish in Africa could be example of evolution in action 2Clot-busting drug helps revive cardiac arrest patients 2
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: